Yellow Zone Practice Parameters for Management of Acute Loss of Asthma Control

Julie Katkin, MD
Associate Professor of Pediatrics
Section of Pulmonary Medicine
Texas Children’s Hospital

David Stukus, MD
Assistant Professor of Pediatrics
Section of Allergy & Immunology
Nationwide Children’s Hospital
Disclosures

• Drs. Katkin and Stukus have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this CME activity.

• We do intend to discuss an unapproved/investigative use of a commercial product/device in our presentation.
Objectives

- Utilize the yellow zone practice parameters to discuss an individualized approach to asthma therapy for patients in clinical practice
- Improve use of written asthma action plans for all patients with asthma
- Apply new concepts regarding use of inhaled corticosteroids into clinical practice
Who Created the Update?

- Joint Task Force (JTF) on Practice Parameters
  - 13-member task force (AAAAI, ACAAI, JCAI)
- 1st JTF Practice Parameter
  - Diagnosis and Treatment of Asthma 1995
- 1st JTF Update
  - Attaining Optimal Control 1998
- Workgroup Formed
  - Systematic literature review
  - Expert opinion

Why the Update?

• Most recent EPR-3 guidelines (2007) emphasized attainment of control and strategies to treat variations in symptoms that occur over months
• Most patients experience intermittent loss of control over shorter time frame
  • Exposure to acute trigger
  • Symptoms worsening over hours to days
• Physician-patient partnership to promote self-management lies at heart of asthma management
• Empower patients to monitor asthma and take action when control deteriorates

1. Journal of Allergy and Clinical Immunology. 2007;120(5):S94-138
How Can This New Information Be Applied?

- Assist self-management when patients begin to experience acute loss of asthma control
- We will be focused on the **YELLOW ZONE** only
- Recommendations are intended to apply in the HOME (school, work) setting only
  - Does not apply to office, emergency department, or hospital
- Can be used to help tailor individual therapy
- Hallmark is use of an individualized asthma action plan for every patient
- **GOAL** = prevent deterioration to **RED Zone** and need for systemic corticosteroids and/or urgent medical care
How Can This New Information NOT Be Applied?

• Not intended to help establish a diagnosis of asthma
• Not intended to help initiate or guide stepwise adjustment to long term controller therapy
• Not intended to assist management in the emergency department
• Not intended to assist management in the hospital setting
GREEN Zone → All systems clear
RED Zone → Too late, seek care
Most Importantly…

- Asthma is NOT “one size fits all”
  - Heterogeneous disease that changes over time
  - Variable symptoms
  - Variable onset
  - Variable duration
  - Variable triggers
  - Variable response to therapy

- So….
  - Definition of loss of control 
  - Management of loss of control

is NOT “one size fits all”
Summary Statement 1

- Asthma action plans typically follow a “traffic light” model
  - Green – daily management when symptoms are well controlled
  - **YELLOW – FOREWARNS ACUTE LOSS OF CONTROL AND IMPENDING EXACERBATION**
  - Red – onset of severe exacerbation requiring course of systemic corticosteroids and contact with health care provider

- Every patient should be provided with an asthma action plan
- Include instructions for recognition of loss of control AND activation of the yellow zone intervention plan
Written Asthma Action Plans

• Providing patients with individual written plans:
  • Decreases symptoms
  • Reduces unscheduled health care visits
  • Improves quality of life
  • Empowers patients to guide self-management

• Written action plans are recommended in all iterations of NHLBI guidelines

• Often under utilized
  • 25% of 18,000 asthmatic children in Chicago schools have plan

Child Asthma Action Plan
0–5 years of age

Health Care Provider’s Name: ____________________  Complete by: ____________________  Date: ____________________

<table>
<thead>
<tr>
<th>Health Care Provider’s Phone #: ____________________</th>
<th>Date: ____________________</th>
<th>Other Instructions (such as spacers/masks, nebulizers)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-Term-Control Medicines (Take every day to stay healthy)</td>
<td>How Much To Take</td>
<td>How Often</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>1 time per day EVERY DAY!</td>
<td>1 time per day EVERY DAY!</td>
<td>1 time per day EVERY DAY!</td>
</tr>
<tr>
<td>Quick-Relief Medicines</td>
<td>Give ONLY as needed</td>
<td></td>
</tr>
<tr>
<td>NOTE: If this medicine is needed often (_______ times per week), call physician.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Child is well** and has no asthma symptoms, even during active play.

**CHILD FEELS AWFUL!** Warning signs may include:
- Child’s wheezes, cough, or difficulty breathing continues or worsens, even after giving yellow zone medicines.
- Child’s breathing is so hard that he/she is having trouble walking/talking/eating/playing.
- Child is drowsy or less alert than normal.

**GREEN ZONE**

**PREVENT** asthma symptoms every day:
- Give the above long-term-control medicines every day.
- Avoid things that make the child’s asthma worse:
  - Avoid tobacco smoke; ask people to smoke outside.

**YELLOW ZONE**

**CAUTION.** Take action by continuing to give regular asthma medicines every day AND:
- Give ______ (include dose and frequency)
- If the child is not in the Green Zone and still has symptoms after 1 hour: then:
  - Give more ______ (include dose and frequency)
  - Call ______ (include dose and frequency)

**RED ZONE**

**MEDICAL ALERT! Get help!**
- Take the child to the hospital or call 9-1-1 immediately!
- Give more ______ until you get help (include dose and frequency)

**Call 9–1–1 if:**
- The child’s skin is sucked in around neck and ribs, or
- Lips and/or fingernails are grey or blue, or
- Child doesn’t respond to you.

Adapted and reprinted with permission from the Regional Asthma Management and Prevention Initiative, a program of the Public Health Institute.

# My Asthma Action Plan

**Patient Name:**

**Medical Record #:**

**Physician’s Name:**

**Physician’s Phone #:**

**Completed by:**

**Date:**

<table>
<thead>
<tr>
<th>Long-Term-Control Medicines</th>
<th>How Much To Take</th>
<th>How Often</th>
<th>Other Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quick-Relief Medicines</th>
<th>How Much To Take</th>
<th>How Often</th>
<th>Other Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Special instructions when I feel**

- **good.**
  - **My peak flow is in the GREEN zone.**
  - My symptoms may include one or more of the following:
    - Wheeze
    - Tight chest
    - Cough
    - Shortness of breath
    - Waking up at night with asthma symptoms
    - Decreased ability to do usual activities

- **I do not feel good.**
  - **My peak flow is in the YELLOW zone.**
  - My symptoms may include one or more of the following:
    - Wheeze
    - Tight chest
    - Cough
    - Shortness of breath
    - It’s getting harder and harder to breathe
    - Unable to sleep or do usual activities because of trouble breathing

- **I feel awful.**
  - **My peak flow is in the RED zone.**
  - Warning signs may include one or more of the following:
    - Wheeze
    - Tight chest
    - Cough
    - Shortness of breath

**PREVENT asthma symptoms everyday:**

- Take my long-term-control medicines (above) every day.
- Before exercise, take _____ puffs of _______.
- Avoid things that make my asthma worse like:

**CAUTION.** I should continue taking my long-term-control asthma medicines every day AND:

- Take ___________.
- If I still do not feel good, or my peak flow is not back in the Green Zone within 1 hour, then I should:
  - Take ___________.
  - Increase ___________.
  - Add ___________.
  - Call ___________.

**MEDICAL ALERT! Get help!**

- Take ___________.
- Until I get help immediately.
- Take ___________.
- Call ___________.

**Danger! Get help immediately!**

- Call 9-1-1 if you have trouble walking or talking due to shortness of breath or lips or fingertips are gray or blue.
Controversy: Are Asthma Action Plans Useful?

- Despite widely adopted use of asthma action plans, there is no evidence in the literature that use of asthma action plans are associated with decreased use of acute resource for asthma care.
- Asthma action plans are not uniform across states, school districts or doctor’s offices – and can’t be.
- Patients are mandated to receive a new plan with each encounter, which can lead to the generation of contradictory information that is more confusing than useful.
Summary Statement 2

• Instruct patients to activate the yellow zone intervention plan when there is acute loss of asthma control in a setting outside a medical care facility, i.e. home.

• Yellow zone is defined as:
  • An increase in asthma symptoms
  • An increase in use of reliever medications
  • A peak flow rate decrease of at least 15% or lower than 80% of personal best
  • The presence or increase in nocturnal asthma symptoms

*Need to consider patient variability in baseline symptoms
What if Yellow Zone is Started Too Early?

• A “false” start may lead to initiation of management when not necessary

BUT...

• Risk of a “late” start may result in episode progression and need for systemic corticosteroids/ER care

Don’t want to be late!
How Much Time From Yellow to Red?

- Substantial variability in literature and real life
- Mean time from 1st appearance to peak of symptoms 5.1 days (range <30 min to >2 weeks)$^1$
- Mean interval peak of symptoms to recovery 6.2 days$^1$
- Often lead time of days to peak of exacerbation
  - Window of opportunity to intervene
- Symptoms may recover before lung function improves
  - Prudent to continue yellow zone management ~2 weeks

Controversy: What About Peak Flow Monitoring?

- Fallen out of favor by many physicians
- Evidence that measurement may not be better predictor than monitoring symptoms\(^1,^2\)
- Use of PEF should be individualized
- Ideal for subset of asthmatics: “poor perceivers”
  - More ER visits, hospitalizations, near-fatal & fatal exacerbations\(^3\)

Summary Statement 3

• Instruct patients to activate the yellow zone plan at the **onset** of an upper respiratory tract infection
  • If this is a previously identified trigger

• URIs one of most common triggers in children
  • May be only trigger
  • In young children, difficult to distinguish WARI from asthma
Controllers at Start of URI

- Montelukast
  - **Not effective in preventing exacerbation requiring steroids**¹
  - With chronic use, can reduce symptom severity and health care usage during URI²
    - Mainly when used in children with + modified API
  - Recommended in Europe for episodic viral wheeze³

- Inhaled Corticosteroids
  - Fluticasone 750 mcg BID at onset of URI in preschool children⁴
    - 50% reduction in need for oral steroids
    - Decreases in height and weight gains
  - Budesonide 1 mg BID x 7 days⁵
    - Not better than placebo
    - Comparable to 0.5 mg daily

---

Summary Statement 4

• Instruct patients to escalate asthma therapy when they experience a loss of asthma control that puts them in the yellow zone
What Are Our Patients Actually Doing?

- Not uncommon for patients to adjust medications on their own
- Large study of 3,415 adults
  - 29% were given acute care plan by MD advising increasing controller meds
  - 52% did so anyway
  - Increase use of both rescue and controller medications
- Patients utilize dynamic dosing on their own to match symptom severity
- Often without direction and inappropriately

Intervention Strategies to Start in Yellow Zone

• Not “one size fits all” – no ideal single strategy

• Consider timing of loss of control
  • Over days (URI)
  • Over hours (exposure to known allergen or irritant)

• Start at onset of symptoms → continue until full recovery (1-2 weeks)

1. Repetitive use of inhaled SABA

2. Scheduled dosing step up
   1. Increasing total ICS dose (at least quadrupling)

3. Dynamic dosing step up
   1. ICS and SABA
   2. ICS and LABA
Summary Statement 5

- Advise patients to use a short acting $\beta_2$ agonist (SABA) for reliever use in yellow zone
- Dose: 2 to 4 puffs every 4 to 6 hours
  - In addition to their escalated yellow zone treatment
- If SABA use exceeds 12 puffs per day $\rightarrow$ advise patients to contact their provider for guidance
SABA Use

- 2007 NHLBI Guidelines
  - 2-6 puffs of SABA every 3-4 hours for 24-48 hours for home use
  - No evidence of explanation for category A rec is provided

- 2011 Global Strategy for Asthma Management and Prevention
  - 2-4 puffs of SABA every 20 min for 1 hour
  - 2-4 puffs of SABA every 3-4 hours with good response
  - 6-10 puffs for moderate exacerbation
MDI vs. Nebulizer

- For mild-to-moderate exacerbation (yellow zone)
- Cochrane Review in 2013\(^1\)
  - 1897 children, 729 adults in 39 trials mainly ED setting
- Use of MDI with spacer equivalent to nebulizer
  - Various markers of clinical outcomes
- Nebulizers associated with more adverse events
  - Tachycardia
  - Tremor
  - Longer LOS

Summary Statement 6

• Advise patients currently treated with daily low-to-moderate dose inhaled corticosteroid (ICS) to consider:

  Increasing the total ICS dose per 24 hours (quadrupling) for managing loss of asthma control in yellow zone
Doubling Dose of ICS

- Previous studies suggested doubling dose of current ICS controller may reduce duration of symptoms, less need for oral steroids
- Recent studies have not demonstrated significant benefit from doubling dose
- However…
  - Significant methodological differences
    - Definition of exacerbation
    - Timing of onset & duration for intervention
    - Primary outcome measures
- So…
  - This may be effective for some patients at certain times
  - Difficult to make blanket recommendations with available data
Quadrupling Dose of ICS

• EPR3 states that quadrupling dose of ICS at start of symptoms and continuing for 7 days may reduce exacerbations

• Similar issues with varying methodologies for studies

• Several demonstrate reduced need for oral steroids, less duration of symptoms

• But…Gasp! That’s a lot of steroids!
  • Typical systemic steroids dosed 2 mg/kg/day, max 60 mg
  • Moderate dose inhaled steroids baseline ~500 mcg/day
  • 500 mcg x 4 = 2000 mcg = 2 mg
Controversy: Increased Inhaled Steroids

- Using very high doses of ICS at first sign of exacerbation requires EARLY recognition of symptoms. This is really difficult with children, who may not recognize or report early signs (especially teens).
- Increased symptoms in very young children must first be recognized by adult caretakers, which will lead to a delay in therapy.
- Not all respiratory infections are associated with wheezing – chance for unnecessary exposure to really high doses of ICS, particularly for very young children.
Summary Statement 7

- For children younger than 6 years with
  - Recurrent wheezing
  - Risk factors for subsequent asthma (positive modified asthma predictive index)
- Consider initiating high-dose ICS or oral montelukast at the early signs of wheezing illnesses to decrease intensity of symptoms
Asthma Predictive Index

• Primary: ≥ 4 wheezing episodes per year

• Secondary:
  At least 1 Major:
  - Parental asthma
  - Physician diagnosed eczema
  - +IgE to at least aeroallergen

  At least 2 Minor:
  - Wheezing apart from colds
  - Peripheral eosinophils ≥4%
  - +IgE to milk, egg, or peanut

Positive mAPI identifies young children more likely to develop true asthma in later childhood

Controversy: Montelukast

• Evidence for montelukast as a useful agent for viral induced wheezing is very thin; use in Europe is based on only a couple of studies
• Use in this manner presumes that one is not on montelukast as daily controller therapy, which is usually how it is used in this country
• At recent Celebration of Pediatric Pulmonology, a group of pediatric pulmonologists voted use of montelukast to treat virus associated wheezes as a good candidate for elimination as part of the “Choosing Wisely” campaign
• Clearly, there are broad differences of opinion here based on experience, and little data
Controversy: Increased ICS with Illness for Toddlers

- Not every child with a cold will go on to wheeze.
- Limited studies available, but those suggest that only 50% of young children who increase ICS with illness escape the need for oral steroids. Potential for “double exposure” to ICS + oral steroids, and delay in treatment.
- Total dose of ICS can be higher for episodic use than with daily low dose ICS, and there is no decrease in frequency of exacerbation requiring OCS.
- Decreased growth rate with high dose episodic ICS in young children.
- I don’t see any benefit here.
Summary Statement 8

• For patients with mild to moderate asthma, consider:
  • Symptom driven use of ICS with concomitant inhaled $\beta$ agonist for control of yellow zone symptoms

• Dynamic dosing step-up with ICS plus albuterol may be considered an option for children and adults whose asthma is mildly persistent
Symptom Driven ICS with or w/o SABA

- IMPACT Trial
  - Adults not on ICS: ICS 200 mcg BID vs zafirlukast 20 mg vs placebo
  - Told to start budesonide 800 mcg BID or prednisone with symptoms
  - Budesonide PRN group (placebo)
    - Similar morning PEF and exacerbations
  - Daily ICS
    - Better results for lung function, symptoms, biomarkers, QoL

Figure 3. Kaplan–Meier Estimates of the Time to a First Exacerbation of Asthma. There was no significant difference among the groups (P=0.39).

TREXA

• Treating Children to Prevent Exacerbations of Asthma

• Study design:
  • 288 children 5 – 18 years old
  • 44 week, randomized, double blind, placebo controlled trial
  • Patients had mild persistent asthma; well controlled & stable on step 2 therapy = low dose ICS

• Randomized into four treatment arms:
  • Combined: Beclomethasone 40 mcg twice daily with ICS 80 mcg + albuterol as needed
  • Daily: Beclomethasone 40 mcg twice daily with albuterol + placebo ICS as needed
  • Rescue: Placebo twice daily with ICS 80 mcg + albuterol as needed
  • Placebo: Placebo twice daily with placebo ICS + albuterol as needed

Primary outcome:
- Time to first exacerbation requiring treatment with systemic corticosteroids

Primary outcome results:
- Compared with the placebo group (49%, 95% CI 37-61), frequency of exacerbations was lower in the **daily** (28%, 18-40, p=0.03), **combined** (31%, 21-43, p=0.07), and **rescue** (35%, 24-47, p=0.07) groups
- Frequency of treatment failure was 23% (95% CI 14-43) in the placebo group, compared with 5.6% (1.6-14) in the combined (p=0.012), 2.8% (0-10) in the daily (p=0.009), and 8.5% (2-15) in the rescue (p=0.024) groups

Secondary outcome:
- Linear growth

Secondary outcome results:
- Linear growth was **1.1 cm (SD 0.3) less** in the **combined and daily arms** (p<0.0001), but not the rescue group (p=0.26)
Figure 4: Linear growth by treatment group
Randomisation took place at week 4.

TREXA: Conclusions

- Children with mild persistent asthma should not be treated with rescue albuterol alone
- The **most effective** treatment to prevent exacerbations in persistent asthmatics is **daily** inhaled corticosteroids
- Inhaled corticosteroids as **rescue medication with albuterol** might be an effective step-down strategy; it is more effective at reducing exacerbations than is use of rescue albuterol alone and does not have associated growth effects

**Why is this study important?**
- 1\textsuperscript{st} study to evaluate “real world” use of ICS therapy in children with intermittent dosing
- Confirmed benefits of use of daily ICS as treatment for persistent asthma
- But…also allowed for possibility of as needed ICS + albuterol in **mild** asthmatics
- Confirmed 1.1 cm reduction in growth velocity with ICS use – now demonstrated with HFA formulation (all prior studies used CFC)
Best Adjustment Strategy for Asthma in Long Term

Rationale:

To determine if adjustment of inhaled corticosteroid therapy based on exhaled nitric oxide or day-to-day symptoms is superior to guideline-informed, physician assessment-based adjustment in preventing treatment failure in adults with mild to moderate asthma.

BASALT: Conclusions

- Among adults with mild to moderate persistent asthma controlled with low-dose inhaled corticosteroid therapy, the use of either biomarker-based or symptom-based adjustment of inhaled corticosteroids was not superior to physician assessment-based adjustment of inhaled corticosteroids in time to treatment failure

- **Why is this important?**
  - Can patients improve asthma control with self-management?
  - Depends upon definition of ‘failure’
  - One of first studies to begin to address ‘real world’ patient driven asthma management
  - Raises new questions re: dosing, end points, etc
Adjusted Maintenance Dosing (AMD): ICS and LABA

- Encourages patient to escalate therapy based upon symptoms by using single inhaler
  - Goal = decrease need for oral corticosteroids
- Multiple recent studies consistently demonstrate efficacy
- AMD therapy standard of care in Canada and Europe

***Important Notation***

This is NOT FDA approved
Many of these studies used Turbuhaler, not MDIs
FDA black boxed warning re: LABAs
NOT studied in children
Dynamic Dosing: Key Points

- Formoterol is the LABA component associated with efficacy
  - Similar to SABA reliever with time to onset of bronchodilation
  - Two current products:
    - Symbicort: budesonide/formoterol
    - Dulera: mometasone/formoterol
- Rationale – patients possess single inhaler to simplify regimen
- Ensures prompt increase in additional ICS dosing when using reliever more frequently
- Symptom driven approach assumes patients recognize worsening asthma symptoms
  - Not ideal for poor perceivers
  - Must have good provider-patient relationship, written action plan
Additional Considerations

- Yellow Zone parameters do not recommend use of ICS/LABA dynamic dosing in children < 18 years of age
- Options without much/strong evidence:
  - Single high dose of ICS
  - SABA plus anticholinergics
  - Montelukast
Controversy: Why Can’t We Do This?

- Dynamic dosing of ICS + formoterol is better studied than most of the recommendations in this guideline, and is successfully implemented in Europe.
- If we were going to have people dropping dead in emergency rooms because of LABA usage, we would be seeing them by now. The black box warning is academic.
- Unfortunately, insurance companies will only pay for one inhaler a month. What do patients do for the rest of the month if they have an exacerbation?
Conclusion

- New efforts to focus on self-management at initial loss of asthma control can hopefully prevent progression to red zone
- Every patient should be given written individualized instructions
  - What to watch for
  - When to escalate therapy
  - What to do & for how long
- Asthma is a heterogeneous disease and treatment is not ‘one size fits all’
THANK YOU FOR LISTENING
TO OUR PRESENTATION